Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions by Cawthorne, C. et al.
For submission to Journal of Labelled Compounds and Radiopharmaceuticals 
Imaging COX-2 expression in cancer using PET/SPECT radioligands: Current status 
and future directions 
Short title:- PET/SPECT imaging of COX-2 expression 
A. Pacelli1, J. Greenman1, C. Cawthorne*1 and G. Smith*1 
1School of Biological, Biomedical and Environmental Sciences, University of Hull, Hull, HU6 
7RX, UK. 
*To whom correspondence should be addressed. Phone +44 (0)1483 626302. Email:- 
C.Cawthorne@hull.ac.uk; Graham.Smith@icr.ac.uk.   
Key words:- coxib, indole, imidazole, [11C]-methylation, PET, SPECT, COX-2, 
prostaglandin, cancer, imaging biomarker 
Abstract 
The role of COX-2 as a driving force in early tumourigenesis and the current interest in the 
combination of COX-2 inhibitors with standard therapy in clinical trials creates an urgent 
need to establish clinically relevant diagnostic tests for COX-2 expression. Molecular 
imaging using small molecule probes radiolabelled for both PET and SPECT offer the 
potential to meet this need, providing a minimally invasive readout for the whole disease 
burden. This review summarises current approaches to the radiolabelling of small  molecule 
COX-2 inhibitors and their analogues for PET and SPECT imaging, and gives an overview 
of their biological evaluation and likely success of clinical application. 
Introduction 
Prostaglandins are an important class of inflammatory signalling molecules with pleiotropic 
effects in tumourigenesis across several of the hallmarks of cancer. They are synthesised 
from arichidonic acid by the cyclooxygenases (COXs), COX-1 and 2, with the former being 
constitutively expressed in most mammalian tissues whilst COX-2 is induced in response to 
variety of pro-inflammatory stimuli. COX-2 is thus expressed in a variety of pathological 
conditions with inflammatory components, including neurodegenerative disorders and 
cancer [1-3]. The lack of basal COX-2 in most normal tissue makes it an attractive biomarker 
for detection via molecular imaging with Positron Emission Tomography (PET) imaging.  
Chronic inflammation has been linked to the development of the majority of cancers, and 
COX-2 expression has been demonstrated in a number of pre-malignant inflammatory 
conditions [4, 5]. The importance of COX-2 expression in the early stages of colon cancer was 
demonstrated when the treatment of patients with familial adenomatous polyposis (FAP) 
with COX-2 inhibitors resulted in the development of significantly fewer adenomas [6]; as 
COX-2 is also overexpressed in several cancers including lung, breast, colon, prostate, head 
and neck, pancreatic and brain [7] the molecular imaging of this target has strong potentialfor 
the early detection of cancer. Additionally, as expression levels of COX-2 have been found 
to be prognostic for progression from ductal carcinoma in situ to invasive cancer in the breast 
and associated with progression and metastasis in prostate cancer [8, 9], imaging COX-2 
may improve the staging of cancer and thus patient management. Importantly, improved 
therapeutic outcomes resulting from the addition of COX-2 inhibitors to standard 
chemotherapy regimens have been correlated to pre-treatment COX-2 levels in several 
malignancies [10-12] with levels of COX-2 also linked to conventional chemoradiation 
responsiveness [13]; thus molecular imaging of COX-2 may allow the stratification of patients 
for COX-2 therapy.  
This review focuses on previous studies of radiolabelled small-molecule COX-2 inhibitors 
and, where available, summarises the biological evaluation of their potential use as imaging 
agents. Where data are available for COX-1/COX-2 probe affinity and selectivity these are 




An early foray into COX-2 probe development was by Prabhakaran et al, who reported the 
synthesis of [11C]celecoxib 1 (Figure 1) as a potential marker for COX-2 overexpression [14]. 
Radiosynthesis via a Stille reaction of a tributylstannyl precursor with [11C]methyl iodide gave 
1 in ~8 % radiochemical yield (RCY). However, no further biological data were provided. An 
alternative palladium catalysed [11C]methylation of celecoxib 1  was carried out by Hirano et 
al in 63 % RCY (d.c.) [15]. The authors further converted [11C]celecoxib to the known 
metabolite [11C]SC-62807 2 by oxidation of the tolyl carbon using potassium permanganate. 
The two radioligands were then evaluated in vivo as potential radiotracers for imaging 
hepatobilary excretion via drug transporters. [11C]celecoxib demonstrated poor suitability for 
imaging this process due to slow blood clearance and the fact that signal will consist of both 
parent and metabolite, but [11C]SC-62807 showing potentially favourable pharmacokinetics. 
No assessment of [11C]celecoxib as a COX-2 imaging agent was made. 
Figure 1 here 
Gao and co-workers synthesised a library of celecoxib derivatives that were radiolabelled 
using [11C]methyl triflate at either the phenolic methyl ether (3) or as the methyl ester (4-7) 
[16]. The non-radiolabelled versions of these compounds were tested in an MTS (cell 
proliferation/viability) assay and were found to inhibit growth of MDA-MB-435 cells with 
similar potency to celecoxib. Crucially, no further biological data were forthcoming in the 
report or any subsequent manuscript to date.  
Table 1 here 
An elegant generic approach to radiolabel COX-2 motifs at the methyl sulfone functionality 
was demonstrated with structures such as etoricoxib (8) and rofecoxib (9). The approach 
involved a thiobutyrate ester as radiolabelling precursor that was deprotected in situ and 
then alkylated using [11C]methyl iodide, followed by oxidation to the methyl sulfone with 
oxone, in high reported RCY (20-30% end of bombardment (EOB)) [17]. A similar strategy 
was adopted by de Vries et al. to radiolabel rofecoxib (9), in this case refined to require just 
a single step alkylation with [11C]methyl iodide, resulting in ~60% RCY and moderate specific 
activity (14 GBq/mol) [18]. These authors assessed [11C]rofecoxib (9) uptake in the brain of 
healthy rats, and demonstrated that this correlated with regions of high basal COX-2 mRNA 
expression; furthermore this accumulation was displaceable by the COX-2 inhibitor NS398. 
[11C]rofecoxib (9) uptake could not be demonstrated in pre-clinical models of inflammation 
based on HSV encephalitis or carageenan-induced paw inflammation, albeit that where 
characterised, there was no significant difference in COX-2 peroxidase activity. 
Tanaka et al synthesised and evaluated three [11C]labelled diaryl-substituted indole and 
imidazole derivatives 10-12 (Figure 1)[19]. The three compounds showed high COX2/COX1 
selectivity and lower logP than standard COX2 radiotracers (Table 1). The compounds were 
demonstrated to have acceptable metabolic stability with approximately 90% parent 
remaining in rat plasma at one hour post-injection for [11C]11  and [11C]12, although [11C]10  
showed reduced metabolic stability with ~50% parent at this time-point. Despite low uptake 
into the brain, all compounds showed differential regional uptake to some extent as 
measured by autoradiography of brain slices; crucially however binding to these and other 
organs was not displaceable by COX-2 inhibitors. [11C]10  was shown to be a P-gp substrate 
but pre-treatment with the P-gp inhibitor cyclosporine A did not modulate brain uptake in 
vivo. None of the compounds showed uptake into a rat AH109A hepatoma model, and the 
authors concluded that [11C]10-12 were sub-optimal COX-2 imaging agents, as a result of 
non-specific binding.  
 
   
[18F]radiolabelling 
The vicinal 1,2-diaryl heterocycle core structure exemplified by celecoxib has provided a 
convenient starting point for many fluorine-18 based COX-2 probes. Prabharakan et al 
radiolabelled celecoxib at the trifluoromethyl position by SN2 displacement of a bromo-
difluoromethyl functionality. The formulated radiotracer [18F]13 (Figure 2) defluorinated in 
the product vial over time however (ca. 6% in 4 hours), with significant defluorination 
(qualitatively assessed by observing bone uptake) also occurring in vivo during imaging  of 
2 hours’ duration. The authors pointed out that defluorination was slower in baboons than in 
rats and could therefore be slower still in humans [20], however [18F]13 was also rapidly 
metabolised in baboons with only 20% parent radiotracer remaining in plasma after 60 
minutes. Toyokuni and co-workers synthesised a similar analogue of valdecoxib, [18F]14, 
that also exhibited rapid in vivo defluorination. Taken together these results suggest that the 
3-pyrazole/isoxazole position is suboptimal for radiolabelling [21]. 
McCarthy and co-workers reported the radiosynthesis [18F]-labelled SC58125 15, by direct 
nucleophilic displacement of the corresponding trimethylammonium triflate, with extensive 
biological evaluation [22, 23]. Although in vitro cell studies showed selective uptake of [18F]-
SC58125 15 that was reversed by pre-incubation with cold SC58125, blocking studies in 
vivo were unsuccessful in rats. As [18F]-SC58125 showed high retention in rat brain 
however, baboon studies were carried out although no pattern of cerebral uptake could be 
discerned that correlated with the known distribution of COX-2. This coupled with the high 
uptake into regions at the base of the brain suggested non-specific binding, again 
questioning the applicability to the clinical setting. 
Desbromo-DuP-697 ([18F]16), a selective COX-2 inhibitor was radiolabelled via nucleophilic 
substitution on the corresponding nitro precursor [24]. Biodistribution studies in rat showed 
displaceable uptake in lung, kidney and heart, all sites where COX-2 is known to be 
expressed. Intestines and fat showed high and non-displaceable uptake, possibly due to 
biliary excretion and to the lipophilicity of the tracer (logP= 3.72 ± 0.16) respectively. In 
studies performed on carrageenan-induced inflammation in rats the inflamed and control 
paws showed similar uptake that was not displaceable by NS-398 or indomethacin; however 
it is worth noting again that COX-2 activity as measured by peroxidise assay was not 
different in the inflamed/non-inflamed paws in this model. The high levels of nonspecific 
binding in the abdomen renders this tracer non suitable for PET-imaging of this area; 
however, the high lipophilicity and consequent ability to cross the blood-brain barrier may 
indicate utility in the measurement of COX-2 levels in neuroinflammation or 
neurodegenerative disorders.  
Uddin et al reported an extensive library of fluorinated indomethacin and celecoxib 
derivatives as potential PET probes [25]. A lead candidate ([18F]17) was radiolabelled by 
simple nucleophilic substitution of a tosylate precursor and then evaluated in vivo using a 
carrageenan-induced inflammation model in male rats, demonstrating higher uptake in the 
inflamed versus control paw. Further evaluation in tumour models showed displaceable 
uptake in HSNCC 1483 xenografts with high COX-2 expression and negligible uptake 
HCT116 xenografts with low COX-2 expression. Stability analysis for the lead radiotracer 
[18F]17 showed defluorination (~9% over 2 hours in vivo) in line with observed defluorination 
for similar radiotracers discussed above.  
Kniess and co-workers studied the indole based radiotracer [18F]18, radiolabelled by 
substitution of a trimethylammonium salt precursor followed by McMurry cyclisation in 10% 
decay corrected RCY and 70-90 GBq/mol specific activity [26]. The radiotracer showed 
uptake in COX-2 expressing cell lines that was blocked by pre-incubation with cold 18. 
Evaluation in vivo showed good metabolic stability with 75% parent radiotracer intact after 
60 min in rat plasma; however evaluation in a mouse HT-29 xenograft model showed no 
significant tumour uptake, leading the authors to conclude that this was likely due to the 
lower affinity of the probe. 
The 5-membered heterocyclic core common to most COX-2 inhibitors invites comparison 
with the 1,2,3-triazole ring typical of Huisgen 1,3-dipolar cycloaddition or “click” chemistry[27]. 
Wuest and co-workers have studied COX-2 inhibitors incorporating a triazole core, 
synthesised by cycloaddition with a copper catalyst to give 1,4-disubstituted triazoles or with 
a ruthenium catalyst to give the more conventional 1,5-disubstitution favoured by COX-2 
inhibitors [28]. Representative lead compounds from both series are shown in Figure 2 (19 
and 20). The 1,4 disubstituted triazoles showed a surprising high affinity for COX-2 given 
the established SAR around this pharmacophore class; however, as expected, the 1,5-
disubstituted triazoles showed greater COX-2 affinity in general. A subsequent paper by the 
same group investigated the use of tetrazoles (eg.g. 21) as the core heterocyclic structure 
but the library of compounds examined showed reduced COX-2 affinity in comparison to the 
lead triazole series exemplified by 19 [29]. Although these approaches may result in improved 
imaging agents, there has been no biological evaluation so far of this class of compounds. 
Figure 2 here 
[123I]- and [125I]-radiolabelling 
Kuge and co-workers synthesised two related iodocelecoxib derivatives, varying in the 
presence of a methyl sulfone or sulfonamide moiety functionalisation (22 and 23 in Figure 
3) by halogenation exchange from a bromine precursor with iodine-125 [30]. The rationale for 
this study was to investigate the possibility that sulfonamide binding to carbonic anhydrases 
in erythrocytes slowed blood clearance for the radiotracers. In vivo evaluation of [125I]22 and 
[125I]23 showed that the sulfonamide derivative [125I]22 cleared more slowly from blood than 
the sulfone counterpart. Further analysis of blood uptake demonstrated that uptake of 
[125I]22 was blocked by incubation with carbonic anhydrase inhibitors such as acetazolamide 
whereas blood uptake of sulfone [125I]23 was unaffected under the same conditions.  
The same group also investigated a radioiodinated derivative of lumaricoxib, [125I]24; a 
weakly acidic COX-2 inhibitor. Introduction of the iodine has a slight effect on COX-2 affinity 
(Table 1) but COX-2/COX-1 selectivity is preserved [31]. [125I]24 was radiolabelled by iodo-
destannylation followed by base-induced hydrolysis of an amide precursor to give the final 
benzoic acid. [125I]24 showed uptake in an in vitro inflammation-induced macrophage model 
that was blocked by incubation with cold 24. Biodistribution in normal rats showed rapid 
clearance from blood but time dependent accumulation in intestines, precluding imaging in 
the abdomen. Competition/blocking experiments to assess the specificity of binding in vivo 
were not carried out in this or the previous study however. 
Uddin and co-workers synthesised a library of sulfonamide and methyl sulfone celecoxib 
derivatives with meta or para iodo subsutitution on the vicinal aryl ring and various 
substituents at the 3-pyrazole position [32]. A lead compound 23 was chosen based on COX-
2 inhibitory profile and radiolabelled with iodine-123 by iodo-destannylation to give [123I]23, 
an alternative radiolabelled version of [125I]23 above and was purified by a simple 
aqueous/organic extraction/phase separation. The radiotracer [123I]23 showed selective and 
displaceable uptake in a carrageenan-induced model of inflammation in the rat paw.  
The same research group also explored the synthesis of indomethacin derivatives in order 
to radiolabel them with iodine-123 [33]. From a COX-2 enzyme assay and a COX-2 inhibition 
assay in intact cell compounds 25 and 26 (Figure 3) were selected for further investigation. 
Radiolabelling via iododestannylation gave the desired radiotracers [123I]25 and [123I]26. The 
lead compound [123I]26 was metabolically stable in vivo and  was able to accumulate in a 
COX-2 expressing tumour in vivo at 3 hours post-injection, although full biodistribution data 
were not reported in this non-radiolabelled study. 
Figure 3 here 
 Conclusion 
Preclinical and clinical studies suggest that measurement of COX-2 expression may have 
application across multiple pathologies. Most imaging strategies to date have focused on 
small molecule probes derived from COX-2 targeted therapeutic agents. Presumably this is 
a result of the intracellular localisation of the COX-2 enzyme, creating the requirement for 
both diffusion of the imaging agent from the extracellular medium to the intracellular 
compartment and efflux from cells that do not contain a COX-2 binding site; characteristics 
routinely optimised for small-molecule therapeutic agents. Of further note, at least one group 
has investigated a peptide based approach to COX-2 imaging, albeit with limited success, 
presumably as a result of poor intracellular localisation of the peptide [34]. 
Although this review has focused on applications in oncology, COX-2 imaging probes have 
potential utility in a range of neurological conditions, due to the impossibility of biopsy. In 
oncology, the detection of pre- or early stage malignant lesions as well as the potential for 
improved staging of disease or stratification of patients for COX-2 inhibitor therapy are 
indicated as major potential applications. Molecular imaging also offers the possibility to 
assess the entire disease burden in vivo, avoiding problems associated with the lability of 
COX-2 protein and mRNA.  
Radiolabelling with [11C] offers the ability to produce probes from existing and well-validated 
COX-2 inhibitors; however, this approach has shown few translatable results to date, 
perhaps because therapeutic agents are commonly optimised to have slow clearance from 
the blood which is contraindicative for their use as imaging agents with short-lived isotopes 
[35]. The necessity of an on-site cyclotron to produce [11C]-labelled tracers also limits the 
clinical application of such tracers. Although this difficulty is removed when labelling with 
isotopes for SPECT, the decreased sensitivity of this technique may also limit the clinical 
success of this approach. Thus the most promising data so far has been derived from the 
use of [18F]-labelled coxib analogues. The design of such agents should take into account 
the observation that primary sulfonamides such as that found on celecoxib also show 
binding affinity to carbonic anhydrases, which may be the underlying cause for many of the 
specificity problems observed with COX-2 probes to date [30, 36]; care should be taken to 
design COX-2 probes that are poor substrates for drug efflux proteins as COX-2 expression 
is often correlated with a resistant phenotype that also expresses multi-drug resistance 
(MDR) proteins such as P-glycoprotein in many cancers.  
It is also worth noting the care necessary to establish reliable models for validation of COX-
2 imaging agents, especially in vivo.  For example, it is difficult to assess candidate probe 
uptake in inflammatory models where COX-2 upregulation cannot be demonstrated [17,23]. 
Similarly, metabolic differences between rodent species may explain a lack of tumour uptake 
where metabolism and target binding have been assessed in rats and mice [25]; such 
differences have been postulated to account for the differential uptake of the TSPO ligand 
[18F]-DPA-714 (Zheng et al, presented at the World Molecular Imaging Conference, Dublin, 
Ireland 5-8th September 2012 and C.Cawthorne, unpublished data). Finally, the gold 
standard for specific in vivo binding is the ability to reduce tumoural uptake by the addition 
of cold compound (ideally not the same molecule) known to bind to the target site.  
An open question is whether the COX-2 expression levels seen in malignancy are amenable 
to detection with radionuclide imaging, especially SPECT. However low receptor density 
targets have been successfully imaged in the brain for many years using PET (e.g. 
dopamine D2 receptor), and low basal expression potentially facilitates a wider dynamic 
range. Another issue is the perceived difficulty of imaging intracellular targets, with  recent 
criteria suggested for selecting imaging biomarkers giving  high weight to the accessibility 
of target on the cell surface[37]. The imaging of intracellular target expression/activity with 
non-substrate tracers considerably widens the range of candidate biomarkers in oncology 
however, and clinical proof-of-concept has been provided with a small molecule inhibitor of 
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Table 1. 
Table 1: IC50 and logP values of several inhibitors. *: LogP values have been calculated 
based on ACDLabs predictions. (ACDLabs Release 12.00, product version 12.01) . a [30], b 
[32] 
Compound                      IC50 (µM) logP 
COX-1 COX-2 
    
1 (Celecoxib) [24]          >4  0.03  4.21±1.49 * 
    
2 (SC-62807)   3.53±1.51* 
    
8 (Etoricoxib) [33]          116±18  1.1±0.1 2.21±0.43 * 
    
9 (Rofecoxib) [32]          18.8±0.9  0.53±0.02  1.34±0.46 * 
    
10 [18]   2.33  
    
11 [18]   2.21 
    
12 [18]   1.89  
    
16 (Desbromo-DuP-697)  [23]   3.72±0.16 
    
17 [24]          >4 0.16 3.06±1.49 * 
    
18 [25]          6.6  1.2 2.3 ± 0.7  
    
20 [26]          20 0.15 1.84±0.85 * 
    













             
         >100  
         >4  
 







         >446±317  2.46±0.78  5.56±1.01 * 
25  [31]          >66 0.12 4.99±0.59 * 
    
26 [31]          >66  0.40 4.94±0.40 * 
    
Valdecoxib [34]          26.1  0.87 1.71±0.56 * 
    
Lumiracoxib [29]          164±75  0.77±0.21 3.90±0.50 * 
    
Indomethacin [24]          0.05  0.75  4.27 [35]  
    
 
 Figure 1. [11C]radiolabelled COX-2 inhibitors. The structures summarised above are mostly 
derived from previously reported therapeutic lead compounds and radiolabelling was in all 
cases carried out by [11C]methylation. 
 Figure 2. [18F]radiolabelled COX-2 inhibitors. As with the [11C]radiolabelled counterparts 
these are primarily derived from therapeutic lead compounds with isolated exceptions. 
 Figure 3. Radioiodinated COX-2 inhibitors. Radiolabelling has focused on SPECT 
applications but the structures and radiochemistry employed is also readily amenable to 
PET radiolabelling with iodine-124. 
 
 
 
